Companies · Biotech
SOUTH SAN FRANCISCO · CA, USA · Biotech · refined from filed group “Other” · founded 2021 · http://mindstate.design
Diligence memoA one-page analyst read on Mindstate Design Labs, Inc. — recommendation, valuation, rhythm, risks.→Mindstate Design Labs, Inc. looks fair against its niche peers and is quiet on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Mindstate Design Labs, Inc. is one of 233 Biotech companies tracked from SOUTH SAN FRANCISCO, CA, USA, on record since 2021. By capital raised it ranks in the upper tier (ahead of 87% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Clinical-stage AI neuroengineering platform
We're making every therapeutically valuable emotion available on demand in pharmaceutical form. Our Osmanthus platform is an ensemble of AI models that synthesize the world’s largest datasets of psychoactive pharmacology and phenomenology, quantitatively pinpointing the combination of neurotransmitter receptor activity that underlies various emotional as well as cognitive and perceptual states. Our lead program MSD-001 is designed to be rapid-acting and produce heightened emotional and cognitive flexibility without hallucinations. MSD-001 is currently in human trials, and will be the base ingredient for multiple drug combination "emotions in a bottle" such as empathy, awe, clarity, or beauty.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.
Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 87% of sector peers (real $). Modeled value above 84% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #5 of 12.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Epsilon3, Inc. | Series A | $15.0M | $217.3M | 4.29× |
| Salish Bioscience Inc. | Series A | $7.0M | $109.6M | 2.17× |
| HB Biotech, Inc. | Series A | $7.8M | $87.8M | 1.74× |
| Acoustic Wave Cell Therapy, Inc. | Series A | $20.5M | $85.0M | 1.68× |
| Mindstate Design Labs, Inc. this company | Series A | $12.7M | $56.2M | 1.11× |
| Nurture Genomics, Inc. | Series A | $4.3M | $53.5M | 1.06× |
| Talus Bioscience, Inc. | Series A | $9.4M | $47.7M | 0.94× |
| Abacus Bioscience Inc. | Series A | $4.4M | $46.6M | 0.92× |
| Ark Biotech Inc. | Series A | $21.7M | $46.0M | 0.91× |
| Escalante Bioscience, Inc. | Series A | $6.7M | $38.1M | 0.75× |
| Zivo Bioscience, Inc. | Series A | $14.6M | $34.1M | 0.67× |
| Unite Genomics, Inc. | Series A | $7.8M | $14.9M | 0.29× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series A | $12.7M | 2024-11-08 | $57.7M | $56.2M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Dillan DiNardo | — | — | 2024-11 |
| Rand Hindi | — | — | 2024-11 |
| Thomas Ray | — | — | 2024-11 |
Mindstate Design Labs, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Tamarind Bio, Inc. | Biotech | Series A | $13.6M | $47.6M | same sector · same stage |
| Montlake Bioscience Inc. | Biotech | Series A | $11.3M | $410.3M | same sector · same stage |
| Zivo Bioscience, Inc. | Biotech | Series A | $14.6M | $34.1M | same sector · same stage |
| Kaneh Bosm Biotechnology Inc. | Biotech | Series A | $10.9M | $90.4M | same sector · same stage |
| Epsilon3, Inc. | Biotech | Series A | $15.0M | $217.3M | same sector · same stage |
| Impact Genomics, Inc. | Biotech | Series A | $10.2M | $369.3M | same sector · same stage |
| Talus Bioscience, Inc. | Biotech | Series A | $9.4M | $47.7M | same sector · same stage |
| CHD Bioscience, Inc. | Biotech | Series A | $18.7M | $3.3M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Osmind Platform for breakthrough mental health research and treatment | Healthtech | — | — | 80% |
| Exin Therapeutics, Inc. AI drug discovery platform for neurotherapeutics | Biotechnology | Seed | $8.5M | 78% |
| Cognition Therapeutics Inc | Biotechnology | Series B | $65.4M | 77% |
| Anthrogen We're training the next generation of protein foundation models. | Biotech | — | — | 77% |
| MentalHappy Inc Group-Therapy Platform for Providers and Health Systems | Healthtech | Pre-Seed | $2.1M | 77% |
| Maven Bio The AI Platform for Life Sciences Intelligence | Biotech | — | — | 77% |
| Mindset Health Building AI therapeutics for physical health conditions like IBS. | Pharma | — | — | 77% |
| Gen1E Lifesciences Inc. AI platform accelerating therapies for rare & inflammatory diseases. | Biotechnology | Series B | $22.5M | 76% |
See where Mindstate Design Labs, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Mindstate Design Labs, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.